Biotech Values

[DewDiligence]

BMY/PFE—No drug recommended by the CHMP has ever been denied approval by the EU, so Apixaban is as good as approved in the EU. It has the potential to be a big enough drug to move the needle even for companies as large as BMY and PFE.

Approval for VTE prevention in the EU may help to some degree with the FDA, although BMY/PFE have not seemed confident about making headway with the FDA in this indication (#msg-58061618).

p.s. The brand name, Eliquis, is a bizarre choice with a sound dangerously close to Elevess (the dermal filler).